

Daniel J George

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2795478/publications.pdf>

Version: 2024-02-01

204
papers

13,200
citations

76196

40
h-index

24915

109
g-index

210
all docs

210
docs citations

210
times ranked

13322
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 1-10.	0.9	4
2	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. <i>European Urology Oncology</i> , 2022, 5, 18-29.	2.6	31
3	Racial disparities in prostate cancer among black men: epidemiology and outcomes. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 397-402.	2.0	37
4	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45.	1.1	4
5	Survival by race in men with chemotherapy-naïve enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 524-530.	2.0	14
6	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. <i>Cancer</i> , 2022, 128, 966-974.	2.0	24
7	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	1
8	Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer. <i>Oncogene</i> , 2022, 41, 1140-1154.	2.6	12
9	Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma. <i>Journal of Geriatric Oncology</i> , 2022, 13, 614-623.	0.5	2
10	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. , 2022, 10, e003844.		42
11	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 306-313.	2.0	5
12	A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 58-64.	2.0	4
13	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 762-769.	2.0	13
14	Setting a new standard for long-term survival in metastatic kidney cancer. <i>Cancer</i> , 2022, 128, 2058-2060.	2.0	0
15	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN γ ± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	3.2	8
16	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 513-523.	2.0	2
17	Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. <i>European Urology Oncology</i> , 2021, 4, 948-954.	2.6	18
18	Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. <i>Future Oncology</i> , 2021, 17, 403-409.	1.1	1

#	ARTICLE	IF	CITATIONS
19	An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC). <i>Oncologist</i> , 2021, 26, e508-e511.	1.9	4
20	Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1271-1278.	0.4	10
21	New approaches to first-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110347.	1.4	25
22	PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS366-TPS366.	0.8	14
23	Survival outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1032-1040.	2.0	28
24	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3317-3328.	3.2	14
25	A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 695-703.	6.3	146
26	Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. <i>Biomarker Research</i> , 2021, 9, 14.	2.8	24
27	LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. , 2021, 9, e001792.		63
28	Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1040-1050.	1.5	17
29	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	2.0	32
30	A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	34
31	Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021, 10, 2341-2349.	1.3	15
32	Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. <i>JCO Global Oncology</i> , 2021, 7, 495-505.	0.8	12
33	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 4077-4088.	3.2	21
34	Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4515-4515.	0.8	5
35	Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas. <i>Genomics</i> , 2021, 113, 1234-1246.	1.3	10
36	A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2954-2965.	2.0	21

#	ARTICLE	IF	CITATIONS
37	Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.01082.	1.4	6
38	Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority Populations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e128-e132.	1.8	2
39	Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. <i>Future Oncology</i> , 2021, 17, 4431-4446.	1.1	4
40	Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. , 2021, 9, e003281.		9
41	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3140-3148.	0.8	72
42	An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6619-6621.	3.2	6
43	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2021, 19, 64-72.	0.1	4
44	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. <i>Biomarker Research</i> , 2021, 9, 80.	2.8	16
45	Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 79.e15-79.e22.	0.8	21
46	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	1.5	18
47	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 284-294.	0.9	91
48	Can I Get a Multidisciplinary Consult, Please? Systemic Immunotherapy and the Timing of Cytoreductive Nephrectomy. <i>European Urology Focus</i> , 2020, 6, 9-10.	1.6	2
49	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	1.4	35
50	The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 376-381.	1.0	5
51	A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. <i>Cancer</i> , 2020, 126, 4485-4497.	2.0	24
52	Racial Disparity in Response to Prostate Cancer Systemic Therapies. <i>Current Oncology Reports</i> , 2020, 22, 96.	1.8	11
53	Novel therapies are changing treatment paradigms in metastatic prostate cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 144.	6.9	80
54	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	1.5	42

#	ARTICLE	IF	CITATIONS
55	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 680-688.	2.0	20
56	Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2187-2196.	13.9	259
57	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. <i>Oncolmmunology</i> , 2020, 9, 1773200.	2.1	10
58	The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100183.	0.7	8
59	Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4863-4868.	3.2	14
60	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1374-1380.	1.1	57
61	Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 39-47.	1.1	3
62	Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. <i>Advances in Therapy</i> , 2020, 37, 2083-2097.	1.3	12
63	Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application. <i>Biosensors and Bioelectronics</i> , 2020, 162, 112250.	5.3	27
64	Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127148.	1.0	12
65	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 509-513.	0.9	1
66	Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3007-3007.	0.8	3
67	Patient preferences and expectations of systemic therapy in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5083-5083.	0.8	6
68	A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5518-5518.	0.8	18
69	HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5602-5602.	0.8	3
70	PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5100-TPS5100.	0.8	6
71	DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5587-TPS5587.	0.8	4
72	Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 80-80.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.. Journal of Clinical Oncology, 2020, 38, 118-118.	0.8	16
74	AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.. Journal of Clinical Oncology, 2020, 38, 184-184.	0.8	1
75	Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 32-32.	0.8	2
76	Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 654-654.	0.8	4
77	Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2020, 38, 730-730.	0.8	8
78	Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 96-96.	0.8	5
79	A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388).. Journal of Clinical Oncology, 2020, 38, TPS268-TPS268.	0.8	5
80	PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, TPS763-TPS763.	0.8	15
81	Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with ipilimumab/nivolumab (I+N).. Journal of Clinical Oncology, 2020, 38, 731-731.	0.8	0
82	Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.. Journal of Clinical Oncology, 2020, 38, 5084-5084.	0.8	0
83	Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.. Journal of Clinical Oncology, 2020, 38, 183-183.	0.8	1
84	Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).. Journal of Clinical Oncology, 2020, 38, 40-40.	0.8	0
85	Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 147-147.	0.8	0
86	PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. Journal of Clinical Oncology, 2020, 38, TPS760-TPS760.	0.8	2
87	Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.. Journal of Clinical Oncology, 2020, 38, 106-106.	0.8	0
88	Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma. Clinical Advances in Hematology and Oncology, 2020, 18, 204-207.	0.3	1
89	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist, 2019, 24, 1497-1501.	1.9	22
90	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. Journal of Clinical Oncology, 2019, 37, 2184-2186.	0.8	7

#	ARTICLE	IF	CITATIONS
91	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e1-813.e9.	0.8	16
92	Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. <i>Cancer Medicine</i> , 2019, 8, 4644-4655.	1.3	55
93	TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF A CLINICAL TRIAL. <i>Neuro-Oncology Advances</i> , 2019, 1, i10-i10.	0.4	0
94	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
95	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1752-1761.	1.2	1
96	A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) A randomized controlled trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 428-437.	2.0	44
97	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
98	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	0.9	42
99	Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2019, 14, e0216934.	1.1	14
100	Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. <i>BMC Cancer</i> , 2019, 19, 548.	1.1	34
101	Prostate Cancer National Summit's Call to Action. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 161-168.	0.9	0
102	Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1106-1116.	1.2	6
103	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1120-1129.	0.8	267
104	Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 588-592.	2.0	14
105	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 11.	1.3	11
106	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-410.	0.8	83
107	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e513-e521.	0.9	31
108	Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities. <i>Clinical Cancer Research</i> , 2019, 25, 2963-2968.	3.2	43

#	ARTICLE	IF	CITATIONS
109	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
110	Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 399-406.	0.6	34
111	Precision Medicine Approaches When Prostate Cancer Akts Up. Clinical Cancer Research, 2019, 25, 901-903.	3.2	6
112	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research, 2019, 25, 1165-1173.	3.2	23
113	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.. Journal of Clinical Oncology, 2019, 37, 4517-4517.	0.8	28
114	Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.. Journal of Clinical Oncology, 2019, 37, 212-212.	0.8	30
115	Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2019, 37, 211-211.	0.8	1
116	Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. Clinical Advances in Hematology and Oncology, 2019, 17, 382-385.	0.3	1
117	Highlights in Advanced Prostate Cancer from the 2019 ASCO Genitourinary Cancers Symposium: Commentary. Clinical Advances in Hematology and Oncology, 2019, 17 Suppl 8, 17-19.	0.3	0
118	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. Targeted Oncology, 2018, 13, 1-20.	1.7	31
119	Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. Clinical Cancer Research, 2018, 24, 1554-1561.	3.2	34
120	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. European Journal of Cancer, 2018, 94, 115-125.	1.3	280
121	Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report. Clinical Genitourinary Cancer, 2018, 16, e509-e512.	0.9	2
122	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. European Urology, 2018, 73, 62-68.	0.9	164
123	Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure. JAMA Oncology, 2018, 4, 702.	3.4	35
124	The promise of immunotherapy in genitourinary malignancies. Precision Clinical Medicine, 2018, 1, 97-101.	1.3	4
125	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer, 2018, 119, 663-669.	2.9	66
126	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 341-348.	0.9	5

#	ARTICLE	IF	CITATIONS
127	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
128	Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival. Carcinogenesis, 2018, 39, 879-888.	1.3	9
129	Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. International Journal of Cancer, 2017, 141, 731-743.	2.3	20
130	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. European Journal of Cancer, 2017, 81, 228-236.	1.3	76
131	Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. Cancer Investigation, 2017, 35, 333-344.	0.6	5
132	Phase I study of pazopanib plus TH-302 in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 611-619.	1.1	8
133	Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 418-424.	0.8	24
134	Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e1137-e1141.	0.9	8
135	Cabozantinib in genitourinary malignancies. Future Oncology, 2017, 13, 755-765.	1.1	3
136	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology, 2017, 35, 591-597.	0.8	584
137	Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Prostate, 2017, 77, 385-395.	1.2	6
138	Reply to B. Rini et al and S. Buti et al. Journal of Clinical Oncology, 2017, 35, 1859-1860.	0.8	1
139	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2017, 35, TPS4596-TPS4596.	0.8	7
140	A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500.. Journal of Clinical Oncology, 2017, 35, TPS4599-TPS4599.	0.8	10
141	Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, e16532-e16532.	0.8	1
142	Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).. Journal of Clinical Oncology, 2017, 35, 4522-4522.	0.8	1
143	The impact of continuing medical education (CME) programs in metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, e18280-e18280.	0.8	0
144	What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence. Therapeutic Advances in Urology, 2016, 8, 272-278.	0.9	14

#	ARTICLE	IF	CITATIONS
145	Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?. American Journal of Roentgenology, 2016, 207, 87-95.	1.0	36
146	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian Journal of Urology, 2016, 3, 268-277.	0.5	4
147	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. New England Journal of Medicine, 2016, 375, 2246-2254.	13.9	640
148	Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 510-518.	0.8	18
149	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e15-530.e21.	0.8	38
150	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology, The, 2016, 17, 378-388.	5.1	327
151	Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, 28-37.e2.	0.9	9
152	Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. Cancer Research, 2016, 76, 1892-1903.	0.4	72
153	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	0.8	1,089
154	Development of a Novel c-MET-Based CTC Detection Platform. Molecular Cancer Research, 2016, 14, 539-547.	1.5	37
155	Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget, 2016, 7, 79828-79841.	0.8	53
156	Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.. Journal of Clinical Oncology, 2016, 34, 273-273.	0.8	0
157	Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. Journal of Oncology Practice, 2015, 11, 491-497.	2.5	67
158	Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, 392-399.	0.9	36
159	Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 110.e1-110.e9.	0.8	17
160	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG-ACRIN Cancer Research Group (E2804). Journal of Clinical Oncology, 2015, 33, 2384-2391.	0.8	75
161	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. European Urology, 2015, 68, 891-898.	0.9	91
162	Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e159-e166.	0.9	17

#	ARTICLE	IF	CITATIONS
163	Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 1063-1069.	1.6	17
164	A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 319-327.	0.9	12
165	Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. <i>BMC Cancer</i> , 2015, 15, 371.	1.1	29
166	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	0.9	35
167	The future of kidney cancer treatment. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 368-71.	0.3	1
168	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3391-3399.	0.8	110
169	Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen. <i>Clinical Cancer Research</i> , 2014, 20, 4218-4227.	3.2	29
170	Copper Signaling Axis as a Target for Prostate Cancer Therapeutics. <i>Cancer Research</i> , 2014, 74, 5819-5831.	0.4	143
171	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 241-250.	0.9	25
172	The effect of gender and age on kidney cancer survival: Younger age is an independent prognostic factor in women with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e9-30.e13.	0.8	41
173	Abstract CT313: An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx). <i>Cancer Research</i> , 2014, 74, CT313-CT313.	0.4	9
174	Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 163-71.	0.3	1
175	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	13.9	2,412
176	A Phase II Trial of Temozolomide in Men With Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 397-406.	0.9	52
177	Bone Marrow Biopsy: RNA Isolation with Expression Profiling in Men with Metastatic Castration-resistant Prostate Cancer—Factors Affecting Diagnostic Success. <i>Radiology</i> , 2013, 269, 816-823.	3.6	54
178	Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4520.	0.8	25
179	Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5076-5076.	0.8	2
180	The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 345-345.	0.8	14

#	ARTICLE	IF	CITATIONS
181	Recent advances in the management of castration-resistant prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 181-3.	0.3	1
182	Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11 Suppl 14, 16-22.	0.3	0
183	Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin. <i>Journal of Clinical Oncology</i> , 2012, 30, 3402-3407.	0.8	138
184	Emerging treatment options for patients with castration-resistant prostate cancer. <i>Prostate</i> , 2012, 72, 338-349.	1.2	28
185	Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401. <i>Journal of Clinical Oncology</i> , 2012, 30, 1534-1540.	0.8	436
186	Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4513-4513.	0.8	9
187	Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4549-4549.	0.8	7
188	Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4612-4612.	0.8	2
189	Impact of salvage therapy with APC8015F on the overall survival (OS) benefit achieved with sipuleucel-T in three phase III studies of metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e15120-e15120.	0.8	0
190	Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer. <i>Journal of Urology</i> , 2011, 186, 877-881.	0.2	44
191	Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO. <i>Blood</i> , 2011, 118, 206-206.	0.6	40
192	HOW DOES SIPULEUCEL-T ALTER OUR CLINICAL PRACTICE?. <i>BJU International</i> , 2010, 106, 945-946.	1.3	0
193	A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3057-3066.	3.2	66
194	The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. <i>European Journal of Cancer</i> , 2010, 46, 517-525.	1.3	118
195	The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery. <i>Blood</i> , 2010, 116, 188-188.	0.6	12
196	Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 51-57.	0.9	21
197	Magnetic Resonance Imaging Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 5548-5554.	3.2	111
198	Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 753s-757s.	3.2	25

#	ARTICLE	IF	CITATIONS
199	Anti-angiogenic therapy in renal cell cancer. <i>BJU International</i> , 2007, 99, 1296-1300.	1.3	12
200	Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 16-24.	0.8	1,590
201	Angiogenesis inhibitors in clinical oncology. <i>Update on Cancer Therapeutics</i> , 2006, 1, 429-434.	0.9	2
202	The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480. <i>Clinical Cancer Research</i> , 2005, 11, 1815-1820.	3.2	152
203	Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma ¹ . <i>Academic Radiology</i> , 2005, 12, 347-357.	1.3	108
204	Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7841-7846.	3.3	282